Botulinum A Toxin in Patients With Parkinson's Disease

• Status: Unknown status
• Trial end date: 2009-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The researchers investigated the effectiveness and safety of BoNT/A injected into the detrusor muscle in patients with PD and MSA all of whom had detrusor muscle overactivity unresponsive to conventional medical therapy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University Of Perugia
• Collaborator: University of Roma La Sapienza
• Treatments: abobotulinumtoxinA; Botulinum Toxins, Type A; incobotulinumtoxinA; onabotulinumtoxinA

Criteria

Inclusion Criteria:

• Patients with overactive bladder symptoms refractory to medical therapy.

Exclusion Criteria:

• Other causes of overactive bladder symptoms including urogenital prolapse and recurrent urinary tract infections were excluded.

• Concomitant anticoagulant therapy or drugs interfering with neuromuscular transmission.

• Neuromuscular disease like Lambert-Eaton syndrome.